trial summary · NCT07635056
Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma
Trial record from the TrialBase DB dataset, status RECRUITING, condition Neuroblastoma, sponsored by Children's Hospital Medical Center, Cincinnati. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be generated from donor cells and infused safely into patients with relapsed or refractory neuroblastoma during dinutuximab-based therapy.
Source record: https://clinicaltrials.gov/study/NCT07635056
Facts
| registry id | NCT07635056 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Neuroblastoma |
| sponsor | Children's Hospital Medical Center, Cincinnati |
| sponsor class | OTHER |
| enrollment | 20 |
| start date | 2026-12 |
| primary completion | 2031-06 |
| completion | 2031-06 |
| results posted | not reported |
Conditions
- Neuroblastoma
Interventions
- CIML-NK Cells
Countries
- United States
Intervention types: BIOLOGICAL
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.